Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Share-based Compensation (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Share-based Compensation for 15 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 21.86% year-over-year to $2.2 million, compared with a TTM value of $5.6 million through Sep 2025, up 17.54%, and an annual FY2024 reading of $5.1 million, down 5.47% over the prior year.
  • Share-based Compensation was $2.2 million for Q3 2025 at Fennec Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.0 million in Q4 2022 and bottomed at -$330000.0 in Q2 2022.
  • Average Share-based Compensation over 5 years is $1.3 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 4266.67% in 2021, then plummeted 78.49% in 2023.
  • Year by year, Share-based Compensation stood at $917000.0 in 2021, then skyrocketed by 334.46% to $4.0 million in 2022, then tumbled by 78.49% to $857000.0 in 2023, then skyrocketed by 31.16% to $1.1 million in 2024, then skyrocketed by 97.42% to $2.2 million in 2025.
  • Business Quant data shows Share-based Compensation for FENC at $2.2 million in Q3 2025, $1.5 million in Q2 2025, and $798000.0 in Q1 2025.